Ads
related to: malignant clones in myeloma life expectancyfreshdiscover.com has been visited by 100K+ users in the past month
explorefrog.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
In hematology, plasma cell dyscrasias (also termed plasma cell disorders and plasma cell proliferative diseases) are a spectrum of progressively more severe monoclonal gammopathies in which a clone or multiple clones of pre-malignant or malignant plasma cells (sometimes in association with lymphoplasmacytoid cells or B lymphocytes) over-produce and secrete into the blood stream a myeloma ...
Smouldering myeloma is a disease classified as intermediate in a spectrum of step-wise progressive diseases termed plasma cell dyscrasias.In this spectrum of diseases, a clone of plasma cells secreting monoclonal paraprotein (also termed myeloma protein or M protein) causes the relatively benign disease of monoclonal gammopathy of undetermined significance.
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [ 10 ]
POEMS syndrome (also termed osteosclerotic myeloma, Crow–Fukase syndrome, Takatsuki disease, or PEP syndrome) is a rare paraneoplastic syndrome caused by a clone of aberrant plasma cells. The name POEMS is an acronym for some of the disease's major signs and symptoms ( p olyneuropathy , o rganomegaly , e ndocrinopathy , m yeloma protein , and ...
Secondary PCL (sPCL) is diagnosed in 1-4% of patients known to have had multiple myeloma for a median time of ~21 months. It is the terminal phase of these patients' myeloma disease. sPCL patients typically are highly symptomatic due to extensive disease with malignant plasma cell infiltrations in, and failures of, not only the bone marrow but also other organs.
Tyrosine kinase inhibitors like imatinib have improved the prognosis of CML patients to near-normal life expectancy. [14] Recently, a JAK2 inhibitor, namely ruxolitinib, has been approved for use in primary myelofibrosis. [15] Trials of these inhibitors are in progress for the treatment of the other myeloproliferative neoplasms.
Ads
related to: malignant clones in myeloma life expectancyfreshdiscover.com has been visited by 100K+ users in the past month
explorefrog.com has been visited by 10K+ users in the past month